| 65.24 -1.2 (-1.81%) | 09-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 89.05 | 1-year : | 97.67 |
| Resists | First : | 76.24 | Second : | 83.62 |
| Pivot price | 70.33  |
|||
| Supports | First : | 64.3 | Second : | 53.5 |
| MAs | MA(5) : | 66.94 |
MA(20) : | 72.58 |
| MA(100) : | 73.37 |
MA(250) : | 74.69 |
|
| MACD | MACD : | -3.3 |
Signal : | -2.5 |
| %K %D | K(14,3) : | 7.9 |
D(3) : | 9.2 |
| RSI | RSI(14): 26.1 |
|||
| 52-week | High : | 99.5 | Low : | 40 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ IRON ] has closed above bottom band by 19.2%. Bollinger Bands are 94.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 10 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 67.08 - 67.45 | 67.45 - 67.75 |
| Low: | 63.45 - 63.97 | 63.97 - 64.4 |
| Close: | 64.47 - 65.25 | 65.25 - 65.88 |
Based in Watertown, Massachusetts, Disc Medicine, Inc. operates as a clinical-stage biotechnology company. Its core mission involves the discovery, development, and commercialization of novel therapeutic solutions for individuals suffering from serious hematological diseases. The company is actively constructing a pipeline of drug candidates, designed to address a variety of these conditions by precisely targeting fundamental biological mechanisms related to red blood cell biology, particularly heme biosynthesis and iron homeostasis.
Sat, 26 Sep 2026
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON - PR Newswire
Mon, 21 Sep 2026
Disc Medicine, Inc. (NASDAQ:IRON) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Wed, 16 Sep 2026
Disc Medicine (NASDAQ: IRON) CEO turns 36,000 options into stock - Stock Titan
Tue, 15 Sep 2026
[Form 4] Disc Medicine, Inc. Insider Trading Activity - Stock Titan
Sat, 12 Sep 2026
Squarepoint Ops LLC Increases Stock Position in Disc Medicine, Inc. $IRON - MarketBeat
Fri, 11 Sep 2026
Officer at Disc Medicine (NASDAQ: IRON) plans to sell 27,136 shares - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 38 (M) |
| Shares Float | 33 (M) |
| Held by Insiders | 7.7 (%) |
| Held by Institutions | 114.3 (%) |
| Shares Short | 7,340 (K) |
| Shares Short P.Month | 7,290 (K) |
| EPS | -6.6 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 16.79 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -24 % |
| Return on Equity (ttm) | -39.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -6.99 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -198 (M) |
| Levered Free Cash Flow | -118 (M) |
| PE Ratio | -9.9 |
| PEG Ratio | 0 |
| Price to Book value | 3.88 |
| Price to Sales | 0 |
| Price to Cash Flow | -12.68 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|